Literature DB >> 19450325

Hyperthyroidism (primary).

Birte Nygaard1.   

Abstract

INTRODUCTION: Hyperthyroidism is characterised by high levels of serum thyroxine and triiodothyronine, and low levels of thyroid-stimulating hormone. The main causes of hyperthyroidism are Graves' disease, toxic multinodular goitre, and toxic adenoma. About 20 times more women than men have hyperthyroidism. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of drug treatments for primary hyperthyroidism? What are the effects of surgical treatments for primary hyperthyroidism? What are the effects of treatments for subclinical hyperthyroidism? We searched: Medline, Embase, The Cochrane Library and other important databases up to June 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 14 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding thyroxine to antithyroid drugs (carbimazole, propylthiouracil, and thiamazole), antithyroid drugs (carbimazole, propylthiouracil, and thiamazole), radioactive iodine, and thyroidectomy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19450325      PMCID: PMC2907936     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  25 in total

1.  The efficacy of thyroidectomy for Graves' disease: A meta-analysis.

Authors:  T K Palit; C C Miller; D M Miltenburg
Journal:  J Surg Res       Date:  2000-05-15       Impact factor: 2.192

2.  Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake.

Authors:  P Laurberg; I Bülow Pedersen; K M Pedersen; H Vestergaard
Journal:  Thyroid       Date:  1999-01       Impact factor: 6.568

3.  Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials.

Authors:  Martin A Walter; Matthias Briel; Mirjam Christ-Crain; Steen J Bonnema; John Connell; David S Cooper; Heiner C Bucher; Jan Müller-Brand; Beat Müller
Journal:  BMJ       Date:  2007-02-19

4.  Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women.

Authors:  J Faber; I W Jensen; L Petersen; B Nygaard; L Hegedüs; K Siersbaek-Nielsen
Journal:  Clin Endocrinol (Oxf)       Date:  1998-03       Impact factor: 3.478

5.  Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery.

Authors:  Mirna Abraham-Nordling; Ove Törring; Bertil Hamberger; Göran Lundell; Leif Tallstedt; Jan Calissendorff; Göran Wallin
Journal:  Thyroid       Date:  2005-11       Impact factor: 6.568

6.  Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal:  N Engl J Med       Date:  1998-01-08       Impact factor: 91.245

7.  Surgery for Graves' disease: total versus subtotal thyroidectomy-results of a prospective randomized trial.

Authors:  J Witte; P E Goretzki; C Dotzenrath; D Simon; P Felis; M Neubauer; H D Röher
Journal:  World J Surg       Date:  2000-11       Impact factor: 3.352

8.  Mortality and vascular outcomes in patients treated for thyroid dysfunction.

Authors:  R W V Flynn; T M Macdonald; R T Jung; A D Morris; G P Leese
Journal:  J Clin Endocrinol Metab       Date:  2006-03-14       Impact factor: 5.958

9.  Frequency of thyroid dysfunction in diabetic patients: value of annual screening.

Authors:  P Perros; R J McCrimmon; G Shaw; B M Frier
Journal:  Diabet Med       Date:  1995-07       Impact factor: 4.359

10.  Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while?

Authors:  A E Jarløv; L Hegedüs; L O Kristensen; B Nygaard; J M Hansen
Journal:  Clin Endocrinol (Oxf)       Date:  1995-09       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.